Answers are grounded in this paper and cite their sources.
Cirrhosis develops histologically as regenerative nodules surrounded by fibrous bands because of chronic liver injury, resulting in portal hypertension and end-stage liver failure. Liver cirrhosis imposes a heavy health and economic burden on many countries. In 2014, Mokdad et al.1 reported the results of the 2010 Global Burden of Disease Study (GBD). Global deaths from cirrhosis increased monotonically from just over 676,000 deaths in 1980 (1.54% of global deaths) to more than 1 million deaths in 2010, or 1.95%. Portal hypertension is a group of disorders characterized by symptoms, such as hepatic encephalopathy. Cirrhosis is the main cause of portal hypertension, accounting for 80%–90% of cases. In addition, cirrhosis has fatal complications that greatly affect the quality of life of patients. Given the increasing popularity of research on portal hypertension and cirrhosis in recent years, we propose using bibliometrics to conduct systematic research to identify research frontier topics and provide suggestions for future research directions. Research in bibliometrics is a quantitative and scientific method for assessing publications that include cluster analysis, co-word analysis, and social network analysis. Recent bibliometric studies2-4 have used VOSviewer (http://www.vosviewer.com) to visualize virtual maps of keywords and their co-occurrence. We used data retrieved from the Web of Science Core Collection (WoSCC) database to perform a bibliometric analysis for portal hypertension and cirrhosis research, using “portal hypertension*,” “portal pressure,” “portal vein pressure,” “liver cirrhosis*,” or “cirrhosis*” as topic subjects. The search included title, abstract, author's keywords, and keywords plus. As a result, we obtained 13,588 studies. We excluded 1873 reviews, editorial materials, books, chapters, proceedings papers, letters, news, items, and corrections from 11,653 studies, leaving articles alone. In total, 9780 articles on portal hypertension and cirrhosis were estimated for specific characteristics such as publication year, journal, author, institution, country, bibliography, and keywords. An analysis of coauthors, co-occurrences, cocitations, and an online visualization were constructed using VOSviewer. Global publications annually increased from 2000 (267 yearly articles) to 2022 (443 yearly), an increase of 165.91%. The World Journal of Gastroenterology published the most manuscripts (361 publications; 9509 citations), followed by Journal of Hepatology (274 publications) and Hepatology (250 publications), which also had the highest number of citations (25,003 citations). The United States (2013 publications, 69,419 citations), University of Barcelona (278 publications, 16,257 citations), and Jamie Bosch (109 publications, 8030 citations) were the most influential and productive country institution, and author, respectively. There were 9780 articles published in the top 10 most cited journals on portal hypertension and cirrhosis, with a median of 17 citations per article. Citations ranged from 649 to 3177 for the top 10 most cited articles. “A model to predict survival in patients with end-stage liver disease,” authored by Kamath et al.5 of the Mayo Clinic and published in Hepatology, was the most cited article (3177 citations). A model for assessing end-stage liver disease (MELD) was developed in this study, which is a reliable indicator of mortality risk in patients with end-stage liver disease and is suitable as an indicator of disease severity to prioritize organ transplant allocation.5 An analysis of the top 100 keywords formed six clusters: (1) mechanism of portal hypertension and cirrhosis; (2) esophageal and gastric varices; (3) liver fibrosis in portal hypertension and cirrhosis; (4) application of TIPS in portal hypertension and cirrhosis; (5) liver transplantation in portal hypertension and cirrhosis; and (6) the relationship between hepatocellular carcinoma, cirrhosis, and portal hypertension. Elastography, spleen stiffness, liver stiffness, esophageal and gastric varices, and upper gastrointestinal bleeding were the latest high-frequency keywords, indicating an emerging frontier in portal hypertension and cirrhosis. Further discussions of the subtopics are provided to help researchers scope the research topic and plan research directions. Cluster 1 includes 26 high-frequency keywords such as ascites, nitric oxide, spontaneous peritonitis, hepatic stellate cells in hepatorenal syndrome, and oxidative stress. Cirrhosis is the most important cause of portal hypertension. Through different mechanisms, it can cause collateral circulation opening, splenomegaly, hypersplenism, and ascites, leading to complications such as gastroesophageal variceal bleeding, hepatic encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome. Cluster 2 includes 20 high-frequency keywords such as gastroesophageal varices, bleeding, endoscopic treatment, embolization, and sclerotherapy. The incidence of gastroesophageal varices in patients with cirrhosis is very high, and approximately 40% of patients with compensated cirrhosis have varied. The risk of bleeding in patients with mild varicose veins was significantly lower than that in patients with severe varicose veins, and the risk of bleeding increased with increasing Child-Pugh score. Cluster 3 includes 20 high-frequency keywords: liver stiffness, chronic liver disease, fiber scanning, ultrasound, CT, MRI, and instantaneous elastic imaging. Liver fibrosis refers to cirrhosis caused by long-term liver inflammation. Healthy liver parenchyma is replaced by fibrotic tissue and regenerative nodules, resulting in portal hypertension. This is a reversible wound-healing process that maintains organ integrity but eventually develops into hepatocellular carcinoma without liver transplantation. Liver fibrosis is generally caused by chronic liver injury due to many factors, including viral infection, schistosomiasis, and alcoholism. Eighteen high-frequency keywords were included in Cluster 4, including TIPS, portosystemic shunt, hepatic encephalopathy, Budd-Chiari syndrome, and portal thrombosis. Transjugular intrahepatic portosystemic shunt (TIPS) is one of the key measures to reduce portal vein pressure in patients with liver cirrhosis and establishes a shunt in the liver parenchyma between the hepatic vein and the portal vein, reducing portal vein resistance in a minimally invasive manner. Currently, TIPS is frequently used to treat esophageal and gastric variceal hemorrhage, intractable hydrothorax and ascites, Budd-Chiari syndrome, and hepatic sinus obstruction syndrome caused by portal hypertension in cirrhosis.6 Seventeen high-frequency terms, including liver transplantation, pulmonary hypertension, hepatitis B, hepatitis C, and prognosis are included in Cluster 5. Nine high-frequency terms, including hepatocellular carcinoma, hypersplenism, and nodular regeneration are part of Cluster 6. Currently, the fundamental precancerous lesion of primary hepatocellular carcinoma is cirrhosis (HCC). Clinical management is particularly challenging because there is no effective therapy for patients with portal hypertension accompanied by HCC. The long-term prognosis is poor, and surgical complications such as upper gastrointestinal hemorrhage and liver failure are often observed. The emphasis of clinical practice is the treatment and management of HCC. In principle, liver transplantation is the greatest therapeutic choice because it treats both the tumor and underlying cirrhosis.7 Using VOS-viewer software to visualize and analyze the data in the current WoSCC, we can see that research in the field of liver portal hypertension and cirrhosis is expanding year by year. Globally, China and the United States dominate the research. The University of Barcelona was the most influential research institution. Co-operation between countries and institutions have advanced scientific research, and more cooperation is required. Jaime Bosch was the most active author in the field. This study sheds light on the current trends, global patterns of collaboration, fundamental understanding, research hotspots, and new frontiers in the field of cirrhosis and portal hypertension. We hope that this article will provide a better guide for future clinical treatments and scientific research (Figure 1). Meng Niu and Zhongqing Wang contributed to conception, design, and final approval of the manuscript. Hongbo Ni, Jian Xue, Fan Wang, and Xiaohan Sun contributed to the sequencing data. The final manuscript was written by Haozhuo Guo. All the authors have read and approved the final version of the manuscript. We are grateful to Zhongqing Wang and his team for their help with this work, as well as to our colleagues in the Department of Interventional Therapy at the First Affiliated Hospital of China Medical University. The authors declare no conflict of interest. Institutional Review Board approval is not required for literature visualization. The data supporting the findings of this study are available from the corresponding author upon reasonable request.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: